drugset

drugset / Trial / NCT02523547

Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude

NCT02523547 ↗

Phase 4 Unknown 134 enrolled Hanmi Pharmaceutical Company Limited

RandomizedParallel-groupOpen-labelTreatment

Summary

Open-labeled, Prospective, Randomized, Multi-center, Interventional, Phase IV study.

Timeline

Start: 2015-01
Primary completion: 2017-02
Completion: 2017-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Entecavir	Small molecule	0.5 mg	—

Indications